Karabay Gulsan, Bayraktar Burak, Seyhanli Zeynep, Cakir Betul Tokgoz, Aktemur Gizem, Sucu Serap Topkara, Tonyali Nazan Vanli, Karabay Umut, Kurt Dilara, Caglar Ali Turhan
Department of Obstetrics and Gynecology, Division of Perinatology, Ankara Etlik City Hospital, Ankara, 06170, Turkey.
Department of Obstetrics and Gynecology, Ankara Etlik City Hospital, Ankara, Turkey.
BMC Pregnancy Childbirth. 2025 Mar 25;25(1):338. doi: 10.1186/s12884-025-07452-z.
To determine the role of sortilin in the pathogenesis of preeclampsia by examining serum sortilin levels in maternal blood.
This prospective case-control study was conducted from May to November 2023 at the Perinatology Clinic of Ankara Etlik City Hospital. The study cohort was divided into two groups: Group 1 consisted of 44 pregnant women diagnosed with preeclampsia, and Group 2 served as the control group, comprising 44 healthy pregnant women. The groups were matched individually, with controls selected based on similar maternal age and gestational age at the time of sample collection.
Maternal sortilin levels were significantly elevated in preeclampsia patients compared to controls. Using a cut-off value of > 3.57 ng/mL, sortilin levels could distinguish preeclampsia cases with a sensitivity of 90.9%, a specificity of 45.5%, and an area under the curve (AUC) of 0.679 (p = 0.002). At a cut-off of > 3.57 ng/mL, it was significantly associated with composite adverse neonatal outcomes, with a sensitivity of 89.6%, a specificity of 36.1%, and an AUC of 0.620 (p = 0.045). In addition, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and protein in 24-hour urine, which are important components in the diagnosis and severity of preeclampsia, were significantly correlated maternal blood sortilin levels.
Our findings indicate that maternal sortilin levels are elevated in patients with preeclampsia compared to those in a healthy pregnant control group. Furthermore, maternal sortilin levels may predict adverse neonatal outcomes. In addition, sortilin levels are correlated key clinical markers of preeclampsia severity.
通过检测孕妇血液中的血清sortilin水平，确定sortilin在子痫前期发病机制中的作用。
本前瞻性病例对照研究于2023年5月至11月在安卡拉埃特利克市医院围产医学诊所进行。研究队列分为两组：第1组由44例诊断为子痫前期的孕妇组成，第2组为对照组，由44例健康孕妇组成。两组进行个体匹配，根据样本采集时相似的产妇年龄和孕周选择对照组。
与对照组相比，子痫前期患者的母体sortilin水平显著升高。使用>3.57 ng/mL的临界值，sortilin水平能够区分子痫前期病例，灵敏度为90.9%，特异性为45.5%，曲线下面积（AUC）为0.679（p = 0.002）。在>3.57 ng/mL的临界值时，它与复合不良新生儿结局显著相关，灵敏度为89.6%，特异性为36.1%，AUC为0.620（p = 0.045）。此外，子痫前期诊断和严重程度的重要组成部分，即天冬氨酸转氨酶（AST）、丙氨酸转氨酶（ALT）和24小时尿蛋白，与母体血液sortilin水平显著相关。
我们的研究结果表明，与健康孕妇对照组相比，子痫前期患者的母体sortilin水平升高。此外，母体sortilin水平可能预测不良新生儿结局。此外，sortilin水平与子痫前期严重程度的关键临床标志物相关。
